MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medic ...

Core Viewpoint - Lifeward Ltd. has received its first prior authorization from a UnitedHealthcare Medicare Advantage Plan for the ReWalk 7 Personal Exoskeleton, marking a significant step in expanding reimbursement pathways for advanced assistive technology for individuals with spinal cord injuries [1][2][3]. Company Summary - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation and deliver groundbreaking solutions [5]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and it operates in the United States, Israel, and Germany [5]. Industry Summary - UnitedHealthcare's approval for the ReWalk 7 demonstrates a commitment to providing access to advanced assistive technology, enhancing mobility and quality of life for individuals with spinal cord injuries [2][3]. - The approval reflects a proactive approach in expanding reimbursement pathways, ensuring reliable access to personal exoskeletons as part of a comprehensive care strategy [3]. - The Centers for Medicare & Medicaid Services (CMS) implemented a reimbursement pathway for personal exoskeletons in 2024, leading to an acceleration in prior authorizations as payer adoption expands [4].

Core Insights - Lifeward Ltd. reported a record quarter for Medicare beneficiary placements, indicating strong commercial execution and operational improvements [3][9] - The company achieved a 16% year-over-year decrease in quarterly cash burn and a 27% decrease in quarterly Non-GAAP operating loss, reflecting ongoing efficiency initiatives [4][6] - Lifeward secured a $3.0 million loan agreement with Oramed Ltd. to support its operations and strategic initiatives [9][10] Financial Performance - Revenue for Q3 2025 was $6.2 million, a slight increase of approximately 1% from $6.1 million in Q3 2024, and an 8% increase from $5.7 million in Q2 2025 [4] - Revenue from traditional products, including ReWalk Personal exoskeletons, rose to $3.1 million, up 24% year-over-year, driven by Medicare-related sales [4] - Gross margin improved to 43.7% in Q3 2025, compared to 36.2% in Q3 2024, primarily due to lower production costs following the closure of the Fremont manufacturing facility [4][5] Operating Expenses and Losses - Total operating expenses in Q3 2025 were $5.9 million, up from $5.4 million in Q3 2024, but adjusted operating expenses decreased to $5.7 million from $6.7 million year-over-year [5] - The operating loss for Q3 2025 was $3.1 million, slightly improved from a loss of $3.2 million in Q3 2024, with adjusted operating loss decreasing to $3.0 million from $4.1 million [6] - Net loss for Q3 2025 was $3.2 million, or $0.20 per share, compared to a net loss of $3.1 million, or $0.35 per share, in Q3 2024 [7] Liquidity and Guidance - As of September 30, 2025, Lifeward had $2.0 million in unrestricted cash and cash equivalents, with cash used in operations improving to $3.8 million from $4.5 million in Q3 2024 [8] - The company reaffirmed its full-year 2025 guidance, expecting revenue in the range of $24 to $26 million and a projected non-GAAP net loss between $12 to $14 million [11]

Core Viewpoint - The recent ruling by an Administrative Law Judge establishes that the ReWalk Exoskeleton is a "reasonable and necessary" medical device for enabling paralyzed individuals to walk, paving the way for Medicare coverage and potentially broader commercial insurance access [1][2]. Group 1: Legal and Regulatory Developments - The ALJ ruling supports an appeal by a Medicare beneficiary for coverage of the ReWalk Exoskeleton, affirming its medical necessity for individuals with spinal cord injuries [1]. - This ruling builds on a prior decision by the Centers for Medicare & Medicaid Services (CMS) in April 2024, which finalized a reimbursement pathway for personal exoskeletons [2]. Group 2: Company Innovations and Products - The ReWalk Exoskeleton is noted as the only personal exoskeleton that allows paralyzed individuals to navigate stairs and curbs, in addition to walking in everyday environments [2]. - The latest model, ReWalk 7, received FDA clearance in March 2025 and is now commercially available in the United States [2]. Group 3: Company Mission and Vision - Lifeward aims to transform the lives of individuals with physical limitations through innovative medical technology, focusing on expanding data and programs for the paralyzed community [2][3]. - The company is committed to delivering groundbreaking solutions that empower individuals to regain mobility and improve their quality of life [3].

Core Insights - Lifeward Ltd. has received approval from a major U.S. health insurance company for the ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access for individuals with spinal cord injuries (SCI) [1][2] - The approval follows the Centers for Medicare & Medicaid Services (CMS) establishing a reimbursement pathway for personal exoskeletons in 2024, which is expected to enhance access for Medicare beneficiaries, who represent about one-third of individuals living with SCI [2][3] Company Overview - Lifeward is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [4] - The company has launched the ReWalk 7, a device designed to assist paralyzed individuals in standing, walking, and navigating everyday environments [3][4] Market Context - The decision by a major commercial health insurer to cover the ReWalk 7 is seen as a pivotal moment that could encourage other insurers to follow suit, thereby solidifying Lifeward's growth trajectory [2][3] - The ReWalk 7 received FDA clearance in March 2025 and was launched for sales in the U.S. on April 15, 2025, indicating a timely entry into the market [1][3]

Core Viewpoint - Lifeward Ltd. has launched the ReWalk 7 Personal Exoskeleton, enhancing the walking experience for individuals with spinal cord injuries through innovative features and improved user control [1][3]. Product Features - The ReWalk 7 includes customizable walking speeds, allowing users to transition smoothly between different environments [5]. - A new Crutch Control feature enables users to manage device functions such as standing, walking, and speed selection with ease [5]. - The introduction of a Wrist Control smartwatch and MyReWalk mobile app facilitates operation mode selection, goal setting, and usage tracking [5]. - Enhanced battery life and improved accessibility features allow users to walk longer distances and navigate stairs and curbs [5][6]. - A new handheld device for therapists improves training efficiency and safety during rehabilitation sessions [5][4]. Development and Feedback - The ReWalk 7 was developed over several years, incorporating feedback from over two dozen end users and physical therapists to optimize its functionality in real-world settings [3][4]. - Clinicians reported that the new features would enhance training sessions, while users expressed increased confidence and control with the updated crutch control unit [4]. Regulatory and Market Access - The ReWalk 7 received FDA clearance in March 2025, following previous advancements in technology and market access for the ReWalk product line [5]. - In 2024, the Centers for Medicare & Medicaid Services finalized a reimbursement pathway for personal exoskeleton use, expanding access for individuals with spinal cord injuries [6]. Company Overview - Lifeward Ltd. is dedicated to developing innovative medical technologies aimed at transforming the lives of individuals with physical limitations or disabilities [8]. - The company’s portfolio includes various products designed for rehabilitation and recovery, emphasizing its commitment to driving innovation in the medical technology sector [8].